NFKB1 and myeloid sarcoma: In patients with MS, the NF-κB pathway is activated, leading to increased pro-inflammatory cytokine expression in brain tissues, particularly in microglia, hypertrophic astrocytes and lymphocytes within active demyelinating plaques (30,31).